Patent US4760156A successfully refreshed from Google Patents.
US4760156A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Platinum co-ordination compounds
Assignee: Johnson Matthey PLC
•
Filing: 1986-06-11
•
Granted: 1988-07-26
•
Expires: 2006-06-11
Abstract
Abstract A platinum co-ordination compound linkable to a monoclonal antibody by a functional group which forms part of a moiety which stabilises the antibody against in vivo hydrolysis. Also the use of such compounds in the treatment of cancer.
Inventors
- 👤 James G. Heffernan
- 👤 Michael J. Cleare
- 👤 Donald H. Picker
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 23:37
CPC Classifications
C; C07; C07F; C07F15/00; C07F15/0006; C07F15/0086; C07F15/0093; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
169 words
A co-ordination compound of platinum linkable to a monoclonal antibody, the compound having the general formula ##STR11## in which A and B are the same or different selected from the class consisting of ammine and monodentate amine or A and B together comprise a bidentate amine, D is selected from the class consisting of substituted methylene and substituted dimethylene, R is selected from the class consisting of hydrogen, lower alkyl, aryl, aralkyl, allkenyl , cyloalkyl, cycloalkenyl, alkoxy and hydroxy, X is a functionalised polymethylene moiety in which the functionalising group is selected from the class consisting of carboxylic acid, alcohol, thiol or amine, y is 1 if D is substituted methylene and is 1 or 2 if D is substituted dimethylene and z is 1 if D is substituted methylene and is 1 or 2 if D is substituted dimethylene, with the proviso that where at least one of A and B is a monodentate cyclic alkylamine X may be a functionalising group selected from carboxylic acid, and thio.
Claim 2
Dependent Claim
169 words
A co-ordination compound of platinum linkable to a monoclonal antibody, the compound having the general formula ##STR11## in which A and B are the same or different selected from the class consisting of ammine and monodentate amine or A and B together comprise a bidentate amine, D is selected from the class consisting of substituted methylene and substituted dimethylene, R is selected from the class consisting of hydrogen, lower alkyl, aryl, aralkyl, allkenyl , cyloalkyl, cycloalkenyl, alkoxy and hydroxy, X is a functionalised polymethylene moiety in which the functionalising group is selected from the class consisting of carboxylic acid, alcohol, thiol or amine, y is 1 if D is substituted methylene and is 1 or 2 if D is substituted dimethylene and z is 1 if D is substituted methylene and is 1 or 2 if D is substituted dimethylene, with the proviso that where at least one of A and B is a monodentate cyclic alkylamine X may be a functionalising group selected from carboxylic acid, and thio.
Claim 3
Dependent Claim
16 words
A compound according to claim 1 in which the polymethylene chain X includes ether or ester.
Claim 4
Dependent Claim
20 words
A compound according to claim 1 in which the A and B groups are both cyclic alkylamine or both ammine.
Claim 5
Dependent Claim
26 words
A compound according to claim 1 in which the functionalised polymethylene moiety X has a total carbon chain length of C 2 to C 20 .
Claim 6
Dependent Claim
63 words
Compounds having the general formula ##STR12## in which A, B, D and R and y have meanings as defined in claim 1, --(CH 2 ) x -- is a polymethylene moiety optionally including ether or ester groups and x is an integer from 1 to 15 and R' is selected from the class consisting of straight chain, branched chain and cyclic alkyl groups.
Claim 7
Dependent Claim
29 words
A pharmaceutical composition for the treatment of cancer and comprising an effective amount of a compound according to claim 1 in association with a pharmaceutically-acceptable carrier, diluent or excipient.
Claim 8
Dependent Claim
9 words
A composition according to claim 6 unit dosage form.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-07-26 | 1992-01-25 | 1992-07-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-07-26 | 1996-01-25 | 1996-07-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-07-26 | 2000-01-25 | 2000-07-26 | $7700.00 | Window Closed / Lapsed |